Future  ||| S:0 E:7 ||| JJ
aspects  ||| S:7 E:15 ||| NNS
of  ||| S:15 E:18 ||| IN
immunotherapy  ||| S:18 E:32 ||| NN
and  ||| S:32 E:36 ||| CC
gene  ||| S:36 E:41 ||| NN
therapy  ||| S:41 E:49 ||| NN
in  ||| S:49 E:52 ||| IN
neuroblastoma  ||| S:52 E:66 ||| JJ
Immunotherapy  ||| S:66 E:80 ||| NNS
against  ||| S:80 E:88 ||| IN
cancer  ||| S:88 E:95 ||| NN
aims  ||| S:95 E:100 ||| VBZ
at  ||| S:100 E:103 ||| IN
stimulating  ||| S:103 E:115 ||| VBG
the  ||| S:115 E:119 ||| DT
immune  ||| S:119 E:126 ||| JJ
system  ||| S:126 E:133 ||| NN
or  ||| S:133 E:136 ||| CC
building  ||| S:136 E:145 ||| VBG
an  ||| S:145 E:148 ||| DT
immune  ||| S:148 E:155 ||| JJ
response  ||| S:155 E:164 ||| NN
against  ||| S:164 E:172 ||| IN
targeted  ||| S:172 E:181 ||| JJ
tumor-associated  ||| S:181 E:198 ||| JJ
antigens  ||| S:198 E:207 ||| NNS
( ||| S:207 E:208 ||| -LRB-
TAAs ||| S:208 E:212 ||| NNP
) ||| S:212 E:213 ||| -RRB-
.  ||| S:213 E:215 ||| .
It  ||| S:215 E:218 ||| PRP
was  ||| S:218 E:222 ||| VBD
proposed  ||| S:222 E:231 ||| VBN
theoretically  ||| S:231 E:245 ||| VBN
as  ||| S:245 E:248 ||| IN
a  ||| S:248 E:250 ||| DT
potential  ||| S:250 E:260 ||| JJ
therapy  ||| S:260 E:268 ||| NN
for  ||| S:268 E:272 ||| IN
cancer  ||| S:272 E:279 ||| NN
over  ||| S:279 E:284 ||| IN
a  ||| S:284 E:286 ||| DT
century  ||| S:286 E:294 ||| NN
ago  ||| S:294 E:298 ||| RB
but  ||| S:298 E:302 ||| CC
it  ||| S:302 E:305 ||| PRP
became  ||| S:305 E:312 ||| VBD
popular  ||| S:312 E:320 ||| JJ
in  ||| S:320 E:323 ||| IN
the  ||| S:323 E:327 ||| DT
past  ||| S:327 E:332 ||| JJ
two  ||| S:332 E:336 ||| CD
decades ||| S:336 E:343 ||| NNS
.  ||| S:343 E:345 ||| .
Gene  ||| S:345 E:350 ||| NN
therapy  ||| S:350 E:358 ||| NN
represents  ||| S:358 E:369 ||| VBZ
a  ||| S:369 E:371 ||| DT
promising  ||| S:371 E:381 ||| JJ
approach  ||| S:381 E:390 ||| NN
for  ||| S:390 E:394 ||| IN
reversing  ||| S:394 E:404 ||| VBG
the  ||| S:404 E:408 ||| DT
neoplastic  ||| S:408 E:419 ||| JJ
phenotype  ||| S:419 E:429 ||| NN
or  ||| S:429 E:432 ||| CC
driving  ||| S:432 E:440 ||| VBG
tumor  ||| S:440 E:446 ||| NN
cells  ||| S:446 E:452 ||| NNS
to  ||| S:452 E:455 ||| TO
self-destruction ||| S:455 E:471 ||| JJ
.  ||| S:471 E:473 ||| .
Although  ||| S:473 E:482 ||| IN
survival  ||| S:482 E:491 ||| NN
rates  ||| S:491 E:497 ||| NNS
of  ||| S:497 E:500 ||| IN
neuroblastoma  ||| S:500 E:514 ||| NNS
( ||| S:514 E:515 ||| -LRB-
NB ||| S:515 E:517 ||| NNP
)  ||| S:517 E:519 ||| -RRB-
with  ||| S:519 E:524 ||| IN
biologically  ||| S:524 E:537 ||| JJ
favorable  ||| S:537 E:547 ||| JJ
disease  ||| S:547 E:555 ||| NN
are  ||| S:555 E:559 ||| VBP
greater  ||| S:559 E:567 ||| JJR
than  ||| S:567 E:572 ||| IN
90 ||| S:572 E:574 ||| CD
% ||| S:574 E:575 ||| NN
,  ||| S:575 E:577 ||| ,
outcomes  ||| S:577 E:586 ||| NNS
of  ||| S:586 E:589 ||| IN
patients  ||| S:589 E:598 ||| NNS
with  ||| S:598 E:603 ||| IN
high  ||| S:603 E:608 ||| JJ
risk  ||| S:608 E:613 ||| NN
disease  ||| S:613 E:621 ||| NN
are  ||| S:621 E:625 ||| VBP
less  ||| S:625 E:630 ||| JJR
than  ||| S:630 E:635 ||| IN
40 ||| S:635 E:637 ||| CD
% ||| S:637 E:638 ||| NN
.  ||| S:638 E:640 ||| .
Stage  ||| S:640 E:646 ||| NNP
4  ||| S:646 E:648 ||| CD
metastatic  ||| S:648 E:659 ||| JJ
NB  ||| S:659 E:662 ||| NN
cases  ||| S:662 E:668 ||| NNS
over  ||| S:668 E:673 ||| IN
18  ||| S:673 E:676 ||| CD
months  ||| S:676 E:683 ||| NNS
of  ||| S:683 E:686 ||| IN
age  ||| S:686 E:690 ||| NN
are  ||| S:690 E:694 ||| VBP
often  ||| S:694 E:700 ||| RB
incurable  ||| S:700 E:710 ||| VBN
with  ||| S:710 E:715 ||| IN
multimodality  ||| S:715 E:729 ||| JJ
chemotherapy  ||| S:729 E:742 ||| JJ
regimens ||| S:742 E:750 ||| NN
.  ||| S:750 E:752 ||| .
In  ||| S:752 E:755 ||| IN
this  ||| S:755 E:760 ||| DT
article ||| S:760 E:767 ||| NN
,  ||| S:767 E:769 ||| ,
translation  ||| S:769 E:781 ||| NN
of  ||| S:781 E:784 ||| IN
immuno-gene  ||| S:784 E:796 ||| JJ
therapy  ||| S:796 E:804 ||| NN
strategies  ||| S:804 E:815 ||| NNS
into  ||| S:815 E:820 ||| IN
clinical  ||| S:820 E:829 ||| JJ
trials  ||| S:829 E:836 ||| NNS
for  ||| S:836 E:840 ||| IN
NB  ||| S:840 E:843 ||| NNP
are  ||| S:843 E:847 ||| VBP
reviewed ||| S:847 E:855 ||| VBN
.  ||| S:855 E:857 ||| .
Future  ||| S:857 E:864 ||| JJ
aspects  ||| S:864 E:872 ||| NNS
of  ||| S:872 E:875 ||| IN
immuno-gene  ||| S:875 E:887 ||| JJ
therapy  ||| S:887 E:895 ||| NN
are  ||| S:895 E:899 ||| VBP
discussed ||| S:899 E:908 ||| VBN
.  ||| S:908 E:910 ||| .
